^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ordspono (odronextamab)

    i
    Company:
    Regeneron, ZAI Lab
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    Apply
    A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1) (NCT06091254)
    Phase 3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/12/2023
    Primary completion :
    04/04/2029
    Completion :
    04/04/2029
    CD20
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Ordspono (odronextamab)
    A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-2) (NCT06097364)
    Phase 3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    11/14/2023
    Primary completion :
    07/29/2029
    Completion :
    07/29/2029
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ordspono (odronextamab)
    A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3) (NCT06091865)
    Phase 3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/13/2023
    Primary completion :
    09/18/2028
    Completion :
    09/18/2028
    CD20
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ordspono (odronextamab)